This announcement follows the FDA’s recent agreements on amendments to the Company’s ADI-001 IND application to evaluate three additional indications beyond lupus nephritis (LN), including ...
Under the authority of the Committee of Ministers and as a subordinate body to the Steering Committee on Anti-discrimination, Diversity and Inclusion (CDADI), the ADI-SOGIESC is instructed to complete ...
Some of the features available in ADI’s portfolio of switching regulators are low battery detector, user adjustable current limit, a variety of switching frequencies, and a reduced number of external ...